June 23, 2022
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting - Advances in Malignant Lymphoma

RESEARCH TRIANGLE PARK, N.C., June 23, 2022 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that new data on the mechanism of action of its lead clinical candidate BTM-3566 will be presented at the Third AACR International Meeting - Advances in Malignant Lymphoma taking place on the 23-26 […]

Read More
April 8, 2022
Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022

RESEARCH TRIANGLE PARK, N.C., April 8th, 2022 - Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, will present new data on its lead drug candidate BTM-3566 at AACR 2022 taking place the 8th-13th of April in New Orleans. The data demonstrate that BTM-3566 co-opts a specific mitochondrial quality control […]

Read More
December 13, 2021
Data on Bantam Pharmaceutical's Lead Drug, BTM-3566 Highlighted During Oral Session on Targeting Mitochondria Pathways in Lymphoid Cancers at the 63rd Annual ASH Meeting

BTM-3566 demonstrated robust therapeutic responses in Diffuse Large B-Cell Lymphoma models, both in vitro and in vivo RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2021 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that data on the activity and mechanism of BTM-3566, a novel, first-in-class oral compound […]

Read More
November 18, 2021
Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology

Bantam Pharmaceutical Announces Data on its lead drug, BTM-3566 to be Presented at the 63rd Annual Meeting of the American Society of Hematology Oral Presentation Will Focus on InVitro and InVivo Responses to BTM-3566 in Diffuse Large B-Cell Lymphoma   RESEARCH TRIANGLE PARK, N.C., November  18, 2021 -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics […]

Read More
September 16, 2021
Bantam Pharmaceutical Completes $25 Million Seed Funding

Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials IND Application Expected in Early 2022 for Its Lead Product BTM-3566 Company Establishes Operations in the Research Triangle Park NEWS PROVIDED BY Bantam Pharmaceutical, LLC Sep 16, 2021, 08:00 ET Bantam plans to submit its Investigational New […]

Read More
April 27, 2021
Bantam Pharmaceutical Appoints Industry Veteran

Bantam Pharmaceutical Appoints Industry Veteran Michael Stocum as President and Chief Executive Officer New York, N.Y. - April 27, 2021 —Bantam Pharmaceutical, a drug discovery, and development company targeting selective modulation of mitochondrial dynamics in cancer, announced today that it has named Michael Stocum, MS as President and Chief Executive Officer. Mr. Stocum succeeds the […]

Read More
We are an early mover in the field of mitochondrial homeostasis, using our pioneering science and unrivaled expertise in mitochondrial cellular biology to revolutionize oncology
We are seeking partners and additional investors to accelerate our clinical research and help bring novel cancer therapies closer to patients in need
Find Out More
Bantam is seeking partners and investors to drive rapid clinical development of our first-in-class molecule from First in Humans trials to clinical Proof of Concept.
CONTACT US
info@bantampharma.com
Top linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram